Protein (2)
Launched (2)
Human (2)
His Tag & Avi Tag (1)His Tag (1)
Biotin-labeled (1)PE Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HLP-H82Ef | HEK293 | Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Complex Protein (Monomer, MALS verified) | ||||
HLP-HP2He | HEK293 | PE-Labeled Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Tetramer Protein |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Superoxide dismutase (Ube Industries) | r-hSOD; FKU-871 | Phase 2 Clinical | Ube Industries Ltd, Astellas Pharma Inc | Myocardial Ischemia; Diabetic Neuropathies | Details |
| Otaplimastat | SP-8203 hydrochloride; SP8203 HCL; SP-8203 | Phase 2 Clinical | Shin Poong Pharmaceutical Co Ltd | Stroke | Details |
| BMX-010 | BMX-010; MnTE-2-PyP; MnTE-2-PyP5+ | Phase 2 Clinical | Duke University | Acne Vulgaris; Rosacea; Psoriasis; Dermatitis, Atopic | Details |
| APB-102 | APB-102; AMT-162 | Phase 2 Clinical | University Of Massachusetts Medical School | Amyotrophic Lateral Sclerosis | Details |
| Rucosopasem manganese | GC-4711 | Phase 1 Clinical | Galera Therapeutics Inc | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bis-choline tetrathiomolybdate | ATN-224; WTX-101; ALXN-1840 | Phase 1 Clinical | Wilson Therapeutics | Hepatolenticular Degeneration; Multiple Myeloma; Prostatic Neoplasms; Melanoma | Details |
| NAS150 | AEOL-10150; NAS150; NAS-150 | Phase 1 Clinical | Aeolus Pharmaceuticals | Supranuclear Palsy, Progressive; Idiopathic Pulmonary Fibrosis; Neoplasms; Lung Injury | Details |
| RAG-17 | RAG-17; RAG17 | Phase 1 Clinical | Amyotrophic Lateral Sclerosis | Details | |
| NI-005 | AP-101 (AL-S Pharma); NI-005 | Phase 1 Clinical | Al-S Pharma Ag | Amyotrophic Lateral Sclerosis | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Orgotein | Approved | Gt Biopharma Inc | Ontosein | Spain | Rheumatic Diseases; Cystitis; Radiation Injuries | null | 1996-01-01 | Cystitis; Radiation Injuries; Rheumatic Diseases | Details | |
| Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate | Approved | American Regent Inc | MULTRYS | United States | Dietary Supplement | American Regent Inc | 2020-07-02 | Dietary Supplement | Details | |
| Tofersen | ISIS-333611; BIIB-067; 99mTc-MAG3-BIIB067 | Approved | Ludwig Institute For Cancer Research, Ionis Pharmaceuticals Inc | QALSODY | United States | Amyotrophic Lateral Sclerosis | Biogen Ma Inc, Biogen Inc | 2023-04-25 | Amyotrophic Lateral Sclerosis | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



